Hemangioblastic characteristics of cancer stem cells in chronic myeloid leukemia

Clinical Laboratory

Volumn 58, Issue 7-8, 2012, Pages 607-613

  Zhu, Xishan ^a   Zhou, Xu ^a   Yang, Lawei ^a   Liu, Gang ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cells; Chronic myeloid leukemia; Hemangioblastic characteristics

Indexed keywords

BCR ABL PROTEIN; VASCULOTROPIN RECEPTOR 2;

ADOLESCENT; ADULT; ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ERYTHROID CELL; FEMALE; GENE EXPRESSION; HEMANGIOBLAST; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ONCOGENE;

EID: 84866082652     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Barnes DJ, Melo JV. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006;5:2862-6.
2. Jørgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+CML cells. Blood 2007;109:4016-9.
3. Jørgensen HG, Copland M, Allan EK, et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 2006;12:626-33.
4. Ries C, Pitsch T, Mentele R, et al. Identification of a novel 82 kDa proMMP-9 species associated with the surface of leukaemic cells: (auto-)catalytic activation and resistance to inhibition by TIMP-1. Biochem J 2007 Aug 1;405(3):547-58.
5. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-76.
6. Fridman R, Toth M, Chvyrkova I, Meroueh S, Mobashery S. Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev 2003;22:153-66.
7. Stefanidakis M, Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood 2006;108:1441-50.
8. Paupert J, Mansat-De Mas V, Demur C. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle 2008 Apr 15;7(8):1047-53. Epub 2008 Jan 18.
9. Redondo-Muñoz J, José Terol M, García-Marco JA. Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood 2008 Jan 1;111(1):383-6. Epub 2007 Sep 21.
10. Redondo-Muñoz J, Escobar-Díaz E, Samaniego R. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006 Nov 1;108(9):3143-51. Epub 2006 Jul 13.
11. Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res 2006 Mar 15;12(6):1828-38.
12. Janowska-Wieczorek A, Majka M, Marquez-Curtis L, Wertheim JA, Turner AR, Ratajczak MZ. BCR-ABL-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 2002 Jun;16(6):1160-6.
13. Kaneta Y, Kagami Y, Tsunoda T, Ohno R, Nakamura Y, Katagiri T. Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. Int J Oncol 2003 Sep;23(3):681-91.
14. Bruchova H, Borovanova T, Klamova H, Brdicka R. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea. Leuk Lymphoma 2002 Jun;43(6):1289-95.
15. Ries C, Loher F, Zang C, Ismair MG, Petrides PE. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res 1999 May;5(5):1115-24.
16. Kim JG, Sohn SK, Kim DH, et al.Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma 2005 Jun;46(6):885-91.
17. Yoon SO, Shin S, Lee HJ. Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinosito 3 kinase/Akt dependent matrix metalloproteinase-9 expression. Mol Cancer Ther 2006; Nov,5(11):344-9.
18. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008;267(1):133-64.
19. Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell production. Blood 2009 Jan 1;113(1):46-57. Epub 2008 Oct 2.
20. Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie CM. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001;98:2615-25.
21. Guo H, Fang B, Zhao RC. Hemangioblastic characteristics of fetal bone marrow-derived Flk1(+)CD31(-)CD34(-) cells. Exp Hematol 2003;31:650-8.
22. Lu Y, Wahl LM. Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKK/NF-κB pathway. J Leuk Bio 2005;78:259-65.
23. Gustin JA, Ozes ON, Akca H, et al. Cell type-specific expression of the IκB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-κ B activation. J Biol Chem 2004;279,1615-20.
24. Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005 Jul 7;436(7047):123-7.
25. Karanes C, Nelson GO, Chitphakdithai P, et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008;14(9 Suppl):8-15.
26. Martin MG, Dipersio JF, Uy GL. Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leuk Lymphoma 2008 Dec 29:1-10.